Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Eat Disord. 2007 Dec;40(8):687-91.

Baclofen for binge eating: an open-label trial.

Author information

1
Department of Psychiatry, Columbia University, New York, New York, USA. aib8@columbia.edu

Abstract

OBJECTIVE:

Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN).

METHOD:

Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks.

RESULTS:

Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants.

CONCLUSION:

In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

PMID:
17647277
DOI:
10.1002/eat.20434
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center